Compare XERS & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | SCL |
|---|---|---|
| Founded | 2005 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.3M | 1.1B |
| IPO Year | 2021 | 1994 |
| Metric | XERS | SCL |
|---|---|---|
| Price | $5.48 | $44.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $10.83 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 2.1M | 142.8K |
| Earning Date | 03-02-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.48% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | $49,590,000.00 | ★ $1,803,737,000.00 |
| Revenue This Year | $28.65 | $6.98 |
| Revenue Next Year | $18.33 | $4.69 |
| P/E Ratio | ★ N/A | $22.14 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $3.81 | $41.82 |
| 52 Week High | $10.08 | $68.00 |
| Indicator | XERS | SCL |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 23.44 |
| Support Level | $4.30 | $41.98 |
| Resistance Level | $5.49 | $45.35 |
| Average True Range (ATR) | 0.24 | 1.33 |
| MACD | 0.00 | -0.31 |
| Stochastic Oscillator | 12.43 | 4.50 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.